Sarcoma  >>  EGFR bi-armed autologous activated T cells  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
NCT02521090: EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

Withdrawn
1/2
0
US
EGFRBi-Armed Autologous T Cells, Laboratory Biomarker Analysis
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Adult Brain Glioblastoma, Adult Gliosarcoma, Recurrent Brain Neoplasm
03/16
 

Download Options